Oaktree Acquisition Corp. III Life Sciences (OACC) stock analysis

Financial Services · Shell Companies

From the 10-K filed 2026-03-26

How it makes money

It generates non-operating income from interest on $191,990,290 held in trust while seeking a healthcare target valued between $500 million and $1.5 billion.

It is a blank check company with no current operating revenues. Its primary financial activity involves holding $191,990,290 of IPO proceeds in a trust account, which generated $8,484,511 in interest income during 2025.

Its future profitability depends entirely on the acquisition of a company in the biopharmaceutical, medical device, or specialized healthcare sectors. It specifically targets businesses with an enterprise value between $500 million and $1.5 billion that can benefit from public currency to fund capital projects or acquisitions.

What growth costs

It pays $25,000 monthly for administrative services and faces $6,719,660 in deferred underwriting commissions payable only upon completing a business combination.

The company maintains a lean cost structure while searching for a target, utilizing $1,434,965 in cash held outside the trust as of late 2025. It pays a fixed monthly fee to its sponsor for office space and administrative support.

The most significant capital requirement is the $6,719,660 deferred underwriting fee, which is contingent on the successful closing of a merger. To bridge any funding gaps for due diligence or transaction costs, the sponsor may provide loans of up to $1,500,000, which are convertible into private placement units at $10.00 each.

What could damage it

If it fails to consummate a business combination by October 25, 2026, it must liquidate the trust account and cease all operations.

The business faces a hard expiration date exactly 24 months after its IPO. If no acquisition is completed by October 25, 2026, the company is legally required to wind up, redeem public shares at $10.00, and liquidate.

This deadline creates a structural risk where potential target companies may gain leverage in negotiations as the liquidation date nears. Failure to close a deal would result in the sponsor losing its entire investment in the founder shares and private placement units, which are not entitled to trust distributions.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.

Other companies in Shell Companies